Comparison of a Panel of Biomarkers Between Gastric Primary Cancer and the Paired Krukenberg Tumor

Abstract

To compare a panel of selected biomarkers between gastric primary cancer and the paired Krukenberg tumor, a total of 21 cases of metastatic tumors originating from stomach and the paired gastric primary cancers were collected. The expressions of a panel of selected biomarkers were tested by IHC. FISH was used to determine the status of HER2/neu in cases scored IHC 2+. The differences of the expressions of the biomarkers were evaluated between metastatic tumors and the paired gastric primary cancers. Bcl-2 was negative in all the cases. The HER2/neu expression was consistent between the gastric primary cancers and the paired metastatic tumors in 17 patients. In the other 4 cases, the HER2/neu expression was negative in gastric primary cancers but positive in the matched metastatic tumors. The concordance rate of c-MET, p53, and Ki-67 expression was 71.4%, 81.0%, and 76.2%, respectively. In conclusion, the expression of Bcl-2 is negative in all gastric primary tumors and the paired metastatic cancers. There is major concordance of the expression of HER2/neu, c-MET, p53, and Ki-67 between gastric primary cancers and the paired metastatic tumors, which suggests that the status of these biomarkers remain stable during the metastatic process.

Bacterial Involvement in Progression and Metastasis of Adenocarcinoma of the Stomach

“…Wang et al found that during the metastasis process, specific biomarkers remain constant, such as HER2/neu, c-met, p53, and ki67, between the primary gastric tumor and the Krukenberg tumor [25]. This is a potential avenue for researchers to explore and understand how the metastasis process occurs.…”